Overview

Michael Houghton (born 1949) is a British-born virologist whose work on the molecular identification of viral hepatitis has had lasting global health impact. He is widely recognized for isolating the hepatitis C virus, a breakthrough that made reliable blood screening and targeted antiviral development possible. For this achievement he shared the 2020 Nobel Prize in Physiology or Medicine with colleagues Harvey J. Alter and Charles M. Rice.

Key discoveries

In 1989 Houghton and collaborators reported the identification of the hepatitis C virus (HCV), the principal cause of non‑A, non‑B post‑transfusion hepatitis. That discovery clarified a major, previously mysterious cause of chronic liver disease. Earlier in the 1980s he also contributed to characterization of the hepatitis D (delta) agent and its genome, work that helped define relationships among hepatotropic viruses (hepatitis D, genomic studies).

Methods and scientific importance

The identification of HCV relied on molecular cloning and immunoscreening strategies applied to nucleic acids derived from infected material. By isolating viral genetic sequences and demonstrating specific immune recognition, researchers were able to develop diagnostic tests to detect HCV antibodies and RNA. These assays drastically reduced transmission through blood transfusion and organ transplantation and created the foundation for direct‑acting antiviral drugs that can now cure most HCV infections.

Applications and public health impact

Houghton’s work changed clinical practice: routine screening of blood products for hepatitis C became standard in many countries, preventing hundreds of thousands of infections. The molecular identification of the virus also focused pharmaceutical research on viral proteins and replication, which ultimately produced highly effective, well‑tolerated treatments. HCV research remains important for liver disease prevention, screening of high‑risk populations, and ongoing eradication efforts.

Awards, career highlights and distinctions

  • Co‑recipient of the 2020 Nobel Prize in Physiology or Medicine for the discovery of hepatitis C (HCV).
  • Recognition across academia and industry for bridging basic virology and translational diagnostics.
  • Contributions to the study and molecular characterization of other hepatitis agents in the 1980s.

Notable fact: the discovery addressed a long‑standing clinical mystery—why many transfusion recipients developed chronic hepatitis despite tests for known viruses—by revealing a previously unidentified viral cause. Houghton’s work illustrates how molecular tools can transform disease detection, prevention, and treatment.